Susceptibility, tumor progression and resistance
Pujana’s Lab

DESCRIPTION

Targeting cancer complexity at origin and progression

Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).

Group members

Miquel Angel Pujana

Group leaders

Principal investigator

Francesca Mateo

Researchers

Research assistant

Roderic Espín

Young investigators

PhD student

Lara Ruiz

Young investigators

PhD student

Arzoo Shabbir

Young investigators

PhD student

Luís Alfaro

Young investigators

PhD student

Publications

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

28 de July de 2016/in Pujana's Lab/by miguel

PLoS One. 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801. eCollection 2016. ABSTRACT Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale mapping at 9p22.2 to identify potential causal variants in BRCA1 and BRCA2 mutation carriers. […]

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

28 de July de 2016/in Pujana's Lab/by miguel

Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787. ABSTRACT Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. Here, using an […]

Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 – Barcelona, Spain)

27 de July de 2016/in Pujana's Lab/by miguel

Drugs Today (Barc). 2016 Jun;52(6):347-54. doi: 10.1358/dot.2016.52.6.2515960. ABSTRACT At the Cancer Therapeutic Resistance: Progress and Perspectives conference, in Barcelona, Spain, April 7-8, 2016, researchers, clinicians and students gathered to discuss our current understanding of intrinsic and acquired resistance of tumors to cancer therapies and to explore how to translate strategies to predict risk or overcome […]

RANKL/RANK control Brca1 mutation-

1 de June de 2016/in Pujana's Lab/by miguel

Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31. ABSTRACT Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations in the breast cancer 1 (BRCA1) or BRCA2 genes markedly increase the risk for the development of breast cancer. Here, […]

Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks

20 de May de 2016/in Pujana's Lab/by miguel

Genome Res. 2016 Jun;26(6):732-44. doi: 10.1101/gr.199935.115. Epub 2016 Apr 13. ABSTRACT Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting to be unveiled. We systematically analyzed mutation, copy number, and gene expression […]

Research Projects

The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.

Collaborations

CIMBA – Consortium of Investigators of Modifiers of BRCA1/2

https://cimba.ccge.medschl.cam.ac.uk/

Lobular Breast Cancer

https://lobsterpot.eu/

BRCA1 breast cancer

Khokha Lab

https://medbio.utoronto.ca/faculty/khokha

Hakem Lab

https://medbio.utoronto.ca/faculty/hakem

Maxwell Lab

https://www.bcchr.ca/cmaxwell

Serra Lab

https://vhio.net/biosketch-violeta-serra/

Cancer biology

Schramek Lab

https://schramek.lunenfeld.ca/

Li Lab

https://lilab.smhs.gwu.edu/

Barcellos-Hoff Lab

https://barcelloshofflab.ucsf.edu/principal-investigator

Cancer genetics

De Cid Lab – GCAT

http://www.gcatbiobank.org/

LAM research

Johnson Lab – LAM UK

https://www.nottingham.ac.uk/medicine/people/simon.johnson

Elżbieta Radzikowska

National Tuberculosis and Lung Diseases Research Institute, Poland

Kwiatkowski Lab

https://www.kwiatkowskilab.org/

AELAM

https://www.aelam.org/

VHIR

https://vhir.vallhebron.com/en/research/pneumology

Molina Lab

https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/

Susceptibility, tumor progression and resistancePujana’s Lab

DESCRIPTION

Miquel Angel Pujana

Group leaders

Francesca Mateo

Researchers

Roderic Espín

Young investigators

Lara Ruiz

Young investigators

Arzoo Shabbir

Young investigators

Luís Alfaro

Young investigators

CONTACT US

Susceptibility, tumor progression and resistance
Pujana’s Lab